<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731091</url>
  </required_header>
  <id_info>
    <org_study_id>GLK-1801</org_study_id>
    <nct_id>NCT03731091</nct_id>
  </id_info>
  <brief_title>To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site
      Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone
      Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed
      Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque
      Psoriasis)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects in each treatment group with treatment success</measure>
    <time_frame>Day 29</time_frame>
    <description>Treatment success defined as none or minimal disease , a score of 0 or 1, within the treatment area(s) on the PGA scale of disease severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects in each treatment group with clinical success</measure>
    <time_frame>Day 29</time_frame>
    <description>Clinical success defined as clear or almost clear, a score of 0 or 1, at the target lesion site on the PASI scale. Each psoriatic sign of scaling, erythema, and plaque elevation should have a score of 0 or 1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">585</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Calcipotriene/ betamethasone dipropionate topical foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical foam once daily for 4 weeks (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enstilar®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical foam once daily for 4 weeks (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical foam once daily for 4 weeks (28 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%</intervention_name>
    <description>Once daily for 4 weeks (28 days)</description>
    <arm_group_label>Calcipotriene/ betamethasone dipropionate topical foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enstilar® foam (LEO Pharma Inc.)</intervention_name>
    <description>Once daily for 4 weeks (28 days)</description>
    <arm_group_label>Enstilar®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo of Calcipotriene/ betamethasone dipropionate topical foam</intervention_name>
    <description>Once daily for 4 weeks (28 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non-lactating female subjects aged at least 18 years at Visit 1.

          2. A clinical diagnosis of stable (at least 6 months) psoriasis vulgaris involving 5% to
             30% body surface area (BSA), not including the face, axilla and groin.

          3. A PGA of disease severity of at least moderate disease severity (Grade ≥ 3).

          4. A plaque elevation of at least moderate severity (Grade ≥ 3) at the target lesion
             site. The most severe lesion at baseline should be identified as the target lesion.

          5. Provide written informed consent. -

        Exclusion Criteria:

          1. Current diagnosis of unstable forms of psoriasis in the treatment area including
             guttate, erythrodermic, exfoliative, or pustular psoriasis.

          2. Other inflammatory skin disease in the treatment area that may confound the evaluation
             of the psoriasis vulgaris (e.g., atopic dermatitis, contact dermatitis, tinea
             corporis).

          3. Presence of pigmentation, extensive scarring, pigmented lesions, or sunburn in the
             treatment areas that could interfere with the rating of efficacy parameters.

          4. History of psoriasis unresponsive to topical treatments.

          5. History of hypersensitivity to any component of the Test or Reference product.

          6. Current or past history of hypercalcemia, calcium metabolism disorder, vitamin D
             toxicity, severe renal insufficiency, or severe hepatic disorders.

          7. Current immunosuppression.

          8. Use within 6 months prior to baseline of biologic treatment for psoriasis (e.g.,
             infliximab, adalimumab, alefacept).

          9. Use within 3 months prior to baseline of: 1) chemotherapy or 2) radiation therapy.

         10. Use within 2 months prior to baseline of: 1) immunosuppressive drugs (e.g.,
             tacrolimus, pimecrolimus) or 2) oral retinoids.

         11. Use within 1 month prior to baseline of: 1) systemic steroids, 2) systemic
             antibiotics, 3) other systemic antipsoriatic treatment, 4) psoralen and ultraviolet A
             (PUVA) therapy, 5) ultraviolet B (UVB) therapy, or 6) systemic anti-inflammatory
             agents. Note: a) Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin use on an
             as-needed basis and if not used consecutively for &gt; 14 days prior to baseline and/or
             during the study is acceptable. Low-dose (81 mg) aspirin taken daily is acceptable. b)
             Intranasal or inhaled corticosteroids are acceptable if kept constant throughout the
             study. Intra-articular steroid injections are permissible.

         12. Use within 2 weeks prior to baseline of: 1) topical antipsoriatic drugs (e.g.,
             salicylic acid, anthralin, coal tar, calcipotriene, tazarotene), 2) topical
             corticosteroids, or 3) topical retinoids.

         13. Use within 2 weeks prior to baseline of: 1) vitamin D supplements 2) vitamin D analogs
             at a dose &gt;400 IU/day; or 3) calcium supplements (including multivitamins containing
             calcium).

         14. Started beta-blocker therapy, antimalarial products, and/or lithium within 3 months of
             baseline. Subjects who have been on a steady dose for at least 3 months prior to
             baseline and will remain on the same dose throughout the study are eligible for study
             participation.

         15. Subjects with planned phototherapy and/or exposure to ultraviolet A (UVA) and/or UVB
             during the study.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Todd Kays</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikhil Sawant</last_name>
    <phone>91 22 6138 3131</phone>
    <phone_ext>205</phone_ext>
    <email>nikhil.sawant@glenmarkpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahesh Deshpande</last_name>
    <phone>91 22 6138 3131</phone>
    <phone_ext>208</phone_ext>
    <email>mahesh.deshpande@glenmarkpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site 20</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 18</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 19</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 15</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 23</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 17</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 22</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 29</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 27</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 1</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 26</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 9</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site 10</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 16</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 21</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 28</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 24</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 8</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 2</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 13</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 7</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational site 31</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 25</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 5</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 11</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 14</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 6</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

